7SXH image
Entry Detail
PDB ID:
7SXH
Keywords:
Title:
BIO-8546 bound GSK3beta-axin complex
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2021-11-23
Release Date:
2023-06-14
Method Details:
Experimental Method:
Resolution:
2.09 Å
R-Value Free:
0.25
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Glycogen synthase kinase-3 beta
Chain IDs:A
Chain Length:347
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:axin peptide
Chain IDs:B
Chain Length:16
Number of Molecules:1
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
PTR A TYR modified residue
Ligand Molecules
Primary Citation
Elucidation of the GSK3 alpha Structure Informs the Design of Novel, Paralog-Selective Inhibitors.
Acs Chem Neurosci 14 1080 1094 (2023)
PMID: 36812145 DOI: 10.1021/acschemneuro.2c00476

Abstact

Glycogen synthase kinase 3 (GSK3) remains a therapeutic target of interest for diverse clinical indications. However, one hurdle in the development of small molecule GSK3 inhibitors has been safety concerns related to pan-inhibition of both GSK3 paralogs, leading to activation of the Wnt/β-catenin pathway and potential for aberrant cell proliferation. Development of GSK3α or GSK3β paralog-selective inhibitors that could offer an improved safety profile has been reported but further advancement has been hampered by the lack of structural information for GSK3α. Here we report for the first time the crystal structure for GSK3α, both in apo form and bound to a paralog-selective inhibitor. Taking advantage of this new structural information, we describe the design and in vitro testing of novel compounds with up to ∼37-fold selectivity for GSK3α over GSK3β with favorable drug-like properties. Furthermore, using chemoproteomics, we confirm that acute inhibition of GSK3α can lower tau phosphorylation at disease-relevant sites in vivo, with a high degree of selectivity over GSK3β and other kinases. Altogether, our studies advance prior efforts to develop GSK3 inhibitors by describing GSK3α structure and novel GSK3α inhibitors with improved selectivity, potency, and activity in disease-relevant systems.

Legend

Protein

Chemical

Disease

Primary Citation of related structures